Uniphar PLC (Ireland:UPR) | RNS | Uniphar PLC
Uniphar plc Currency Change on London Stock Exchange
The currency in which Uniphar’s ordinary shares are traded on Euronext Dublin will remain Euro. The Company’s financial statements will continue to be presented in Euro.
For further details contact:
Uniphar |
+353 (0) 1 428 7777 |
|
|
|
|
Group Director of Corporate Development |
|
|
|
Davy |
+353 (0) 1 679 6363 |
(Joint Corporate Broker, Nominated Adviser and Euronext Growth Adviser) |
|
|
|
|
|
|
|
|
|
|
|
RBC Capital Markets (Joint Corporate Broker) |
+44 (0) 20 7653 4000 |
|
|
|
|
|
|
|
|
|
|
Stifel Nicolaus Europe Limited (Joint Corporate Broker) |
+44 (0) 20 7710 7600 |
|
|
|
|
|
|
|
|
Q4 PR |
+353 (0) 1 475 1444 or |
(Public Relations Adviser to Uniphar) |
+353 87 235 6461 |
|
|
|
|
About Uniphar plc
Headquartered in
The Group has strong established relationships with 7 of the top 10 pharma companies and 6 of the top 10 medical device companies. With a workforce of more than 2,500, the Group is active in
The Group’s vision is to improve patient access to pharmaco-medical products and treatments by enhancing connectivity between manufacturers and healthcare stakeholders. Uniphar represents a strong combination of scale, growth and profitability.
Commercial & Clinical
In Commercial & Clinical the Group provides sales, marketing & distribution solutions to multinational pharmaceutical and medical device manufacturers on an outsourced basis. Active in
Product Access
In Product Access the Group is growing two distinct service offerings: 1) “On Demand Access”, which are pharmacy led solutions for sourcing and supplying unlicensed medicines to meet the needs of both retail and hospital pharmacists; and 2) “Exclusive Access”, which are manufacturer led solutions for controlling the release of speciality medicines for specifically approved patient populations in agreed markets. The Group currently delivers product access solutions on a global basis.
Supply Chain & Retail
Uniphar is an established market leader in